Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q2

2784.TEDINET S100PL0M
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.33T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥2.59T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.29T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥10.2bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥9.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥11.5bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥32.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.0bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥11.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥10.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥32.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥7.0bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.33Tat 2022-09-30Cons.Assets
Total assets¥1.30Tat 2022-03-31Cons.Assets
Total assets¥1.33Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥852.3bnat 2022-09-30Cons.Liabilities
Total liabilities¥832.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥481.9bnat 2022-09-30Cons.Net assets
Net assets / equity¥471.8bnat 2022-03-31Cons.Net assets
Net assets / equity¥492.0bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥169.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥180.4bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥168.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥179.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥176.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥169.1bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥36.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥20.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥15.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥2.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥29.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥34.62022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.12022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥153.572021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥33.022021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.72021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio36.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.9%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥245m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.18T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.17T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥8.3bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥23.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥842m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥14m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥124.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥123.8bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥305m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.35T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.33T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥15.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥10.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥14.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥14.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥182m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.13T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.13T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥7.9bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥7.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥22.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥6.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥16.8bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.8bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2021-04-01 → 2021-09-30−¥285m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥129.9bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥129.6bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥284m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.30T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.29T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥14.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥8.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 539
ItemContextValueUnit
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember1096000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember-285000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember8934000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember182000000JPY
Operating incomePrior1YTDDuration9117000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember1173756000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember123764000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember17018000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember17879000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1332419000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration1332419000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember8338000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember305000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember6597000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember15240000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-15240000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember1182094000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember124070000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember23616000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember17879000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1347660000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-15240000000JPY
Net salesCurrentYTDDuration1332419000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember7994000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember1158000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember842000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember-14000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9981000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember245000000JPY
Operating incomeCurrentYTDDuration10227000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-11-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第20期第２四半期(自 2022年７月１日　至 2022年９月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)アルフレッサ ホールディングス株式会社
Company name in english cover pageFilingDateInstantAlfresa Holdings Corporation
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　荒川　隆治
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都千代田区大手町一丁目１番３号
Telephone number address of registered headquarter cover pageFilingDateInstant03-5219-5100
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役 副社長社長補佐・財務企画・コーポレートコミュニケーション担当岸田　誠一
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都千代田区大手町一丁目１番３号
Telephone number nearest place of contact cover pageFilingDateInstant03-5219-5100
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役 副社長社長補佐・財務企画・コーポレートコミュニケーション担当岸田　誠一
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE02962
Fund codeFilingDateInstant－

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass